Author(s):
Saravanan. R, Somanathan. T, Gavaskar D, Tamilvanan M
Email(s):
soma_nano@yahoo.co.in
DOI:
10.52711/0974-360X.2021.00428 
Address:
Saravanan. R1, Somanathan. T1*, Gavaskar D1, Tamilvanan M2
1Department of Chemistry, Vel’s Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai, India
2Department of Chemistry, K.S.R College of Engineering, Tiruchengode, Namakkal, India
*Corresponding Author
Published In:
Volume - 14,
Issue - 5,
Year - 2021
ABSTRACT:
A novel, economic, simple, precise and time-efficient reverse-phase high performance liquid chromatographic (RPHPLC) method has been established for the simultaneous assay determination of Dolutegravir, Lamivudine and Tenofovir Disoproxil fumarate in tablet formulation. This research paper presents the detailed method development strategy and the outcome of validation challenges. The RPHPLC method was developed using a 150 x 4.6mm, 5µm C18 column, with a gradient mode using 0.1% (v/v) trifluoroacetic acid buffer and methanol, the detection was performed at 260nm. The method was validated for specificity, precision, linearity, accuracy, robustness and can be used in quality control during manufacture and for assessment of the stability samples of Dolutegravir/Lamivudine/Tenofovir Disoproxil fumarate tablets. Total elution time was about 5 min and equilibration time of about 2 min which allows analysis of more than 100 samples per day. The method reported in this study is compatible to mass spectrometry and is thus extremely useful for stability studies.
Cite this article:
Saravanan. R, Somanathan. T, Gavaskar D, Tamilvanan M. Analytical Method Development and Validation of Stability Indicating assay method of analysis for Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate tablets using High Performance Liquid Chromatography Research Journal of Pharmacy and Technology. 2021; 14(5):2434-9. doi: 10.52711/0974-360X.2021.00428
Cite(Electronic):
Saravanan. R, Somanathan. T, Gavaskar D, Tamilvanan M. Analytical Method Development and Validation of Stability Indicating assay method of analysis for Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate tablets using High Performance Liquid Chromatography Research Journal of Pharmacy and Technology. 2021; 14(5):2434-9. doi: 10.52711/0974-360X.2021.00428 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-5-12
REFERENCES:
1. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Garvey EP, Johns BA, Gartland MJ, Foster SA, Miller WH, Ferris RG, Hazen RJ, Underwood MR, Boros EE, Thompson JB, Weatherhead JG, Koble CS, Allen SH, Schaller LT, Sherrill RG, Yoshinaga T, Kobayashi M, Wakasa-Morimoto C, Miki S, Nakahara K, Noshi T, Sato A, Fujiwara T. Antimicrob Agents Chemother. 2008 Mar; 52(3): 901-8.
2. Dolutegravir-a review of the pharmacology, efficacy, and safety in the treatment of HIV. Christopher E Kandel, Sharon L Walmsley. Drug Design, Development and Therapy 2015:9 3547-3555.
3. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, SINGLE Investigators. N Engl J Med. 2013 Nov 7; 369(19): 1807-18.
4. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food. Weller S, Chen S, Borland J, Savina P, Wynne B, Piscitelli SC. J Acquir Immune Defic Syndr. 2014 Aug 1; 66(4): 393-8.
5. Drugs for HIV Infection. Benjamin J. Eckhardt, Roy M. Gulick, in Infectious Diseases (Fourth Edition), 2017
6. Laboratory Diagnosis and Therapy of Infectious Diseases. David W. Kimberlin, Principles and Practice of Pediatric Infectious Diseases (Fourth Edition), 2012
7. A stability-indicating HPLC method for the determination of potential impurities in a new fixed dose combination of dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets used in the first line treatment of HIV-1 infection. Varaprasad Jagadabi, P.V. Nagendra Kumar, Srinivasu Pamidi, Lanka.A.Ramaprasad, D.Nagaraju, Analytical RandD, Hetero Labs Ltd, Hyderabad, Telengana, India Int. Res. J. Pharm. 2018, 9 (5)
8. Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus. William E. Delaney, IV, Adrian S. Ray, Huiling Yang, Xiaoping Qi, Shelly Xiong, Yuao Zhu, and Michael D. Miller. Antimicrob Agents Chemother. 2006 Jul;50(7): 2471-7.
9. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Kearney BP, Flaherty JF, Shah J Clin Pharmacokinet. 2004; 43(9): 595-612.
10. Tenofovir Disoproxil Fumarate in the Clinical Practice: An Overview. Maria Foggia, Salvatore Nappa, Giovanni Bonadies, Mariarosaria Cotugno, Giovanni Di Filippo, Francesco Borrelli, Raffaele Orlando, Guglielmo Borgia. Anti-Infective Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Infective Agents) Volume 7, Issue 4, 2008 [285 - 295]
11. Development and validation of stability indicating HPLC method for simultaneous determination of Lamivudine, Tenofovir, and Dolutegravir in bulk and their tablet dosage form. Nagasarapu Mallikarjuna Rao, Dannana Gowri Sankar. Future Journal of Pharmaceutical Sciences Volume 1, Issue 2, December 2015, Pages 73-77
12. ICH guideline: https://database.ich.org/sites/default/files/Q2_R1__Guideline.pdf